FDA Approved Aprocitentan, an endothelin receptor antagonist for the treatment of resistant hypertension [Ref].
Aprocitentan is to be marketed under the brand name, TRYVIO.
Aprocitentan is an endothelin receptor antagonist prescribed for the management of hypertension, in conjunction with other antihypertensive agents.
Its primary indication is to decrease blood pressure in adult patients inadequately responsive to other blood pressure-lowering medications.
By improving hypertension, TRYVIO effectively diminishes the risk of both fatal and non-fatal cardiovascular events, predominantly strokes and myocardial infarctions.
The recommended dose is 12.5 mg once daily
Aprocitentan is contraindicated in pregnant women.
It may also cause liver damage, anemia, fluid retention, allergic reactions, and male infertility.
It is not recommended in moderate to severe liver impairment and in advanced kidney disease (eGFR of <15 ml/minute)